<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6809658</article-id><article-id pub-id-type="doi">10.1093/ofid/ofz360.2328</article-id><article-id pub-id-type="publisher-id">ofz360.2328</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>2650. Evaluating Antiviral Agents for Human Noroviruses Using a Human Intestinal Enteroid Model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cortes-Penfield</surname><given-names>Nicolas W</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Ramani</surname><given-names>Sasirekha</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Neill</surname><given-names>Frederick</given-names></name><degrees>MA</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Ettayebi</surname><given-names>Khalil</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Atmar</surname><given-names>Robert</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Estes</surname><given-names>Mary</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>University of Nebraska Medical Center</institution>, Omaha, Texas</aff><aff id="AF0002"><label>2</label>
<institution>Baylor College of Medicine</institution>, Houston, Texas</aff><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><pub-date pub-type="epub" iso-8601-date="2019-10-23"><day>23</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>10</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>6</volume><issue>Suppl 2</issue><issue-title>IDWeek 2019 Abstracts</issue-title><fpage>S927</fpage><lpage>S928</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2019</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofz360.2328.pdf"/><abstract><title>Abstract</title><sec id="s2"><title>Background</title><p>Norovirus can cause chronic infections with serious morbidity and mortality in immunocompromised patients. While there are no FDA-approved medications for these infections, nitazoxanide, ribavirin, and enterally administered pooled immunoglobulin (IVIG) are used off-label on the basis of expert opinion. Nitazoxanide and ribavirin show antiviral activity in a murine norovirus infection model and an <italic>in vitro</italic> replicon model of genotype GI.I human norovirus RNA expression, respectively. However, these drugs have not been evaluated in <italic>in vitro</italic> infections with GII.4 human noroviruses, responsible for most human norovirus disease. We used the stem cell-derived nontransformed human intestinal enteroid (HIE) system, which supports GII.4 human norovirus replication, to evaluate the antiviral activities of nitazoxanide, ribavirin, and IVIG.</p></sec><sec id="s3"><title>Methods</title><p>We inoculated HIEs with GII.4 human norovirus in the presence of half-log dilutions of nitazoxanide (3 &#x000b5;M to 100 &#x000b5;M), ribavirin (10 &#x000b5;M to 10 mM), or IVIG (1:100 to 1:3,000) and a media control. One and 48 hours after inoculation, we extracted and quantified GII.4 norovirus RNA from the HIEs. To demonstrate that replication inhibition was not due to cytotoxicity, we performed quantitative lactate dehydrogenase release assays on the HIEs across the therapeutic range of each compound.</p></sec><sec id="s4"><title>Results</title><p>Nitazoxanide reduced GII.4 replication at 48 hours in a dose-dependent manner, achieving a &#x0003e;90% reduction in viral replication at 10 &#x000b5;M without cytotoxicity. These findings were confirmed in multiple HIE lines representing different intestinal segments and established from different donors. IVIG completely inhibited GII.4 replication at up to a 1:1,000 dilution and was not cytotoxic at therapeutic concentrations. Ribavirin did not reduce GII.4 replication at concentrations up to 10 mM&#x000b5;M, well in excess of levels achieved in human sera with standard doses.</p></sec><sec id="s5"><title>Conclusion</title><p>Nitazoxanide and IVIG, but not ribavirin, potently inhibit GII.4 human norovirus replication in a biologically relevant in vitro model of human norovirus infection. These data highlight the use of HIEs as a new pre-clinical model for developing therapeutics for human norovirus disease.</p></sec><sec id="s6"><title>Disclosures</title><p>
<bold>All authors:</bold> No reported disclosures.</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front><back><notes id="n1"><p>
<bold>Session:</bold> 272. Studies of Treatment and Prevention of Viral Disease</p><p>
<italic>Saturday, October 5, 2019: 12:15 PM</italic>
</p></notes></back></article>